January 04, 2024

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

December 20, 2023

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

December 08, 2023

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2023

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2023

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

November 06, 2023

“Extra-Strength” 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting

November 01, 2023

Evolus to Participate in November Investor Conferences

October 25, 2023

Evolus to Report Third Quarter 2023 Results

October 25, 2023

Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting

September 29, 2023

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 29, 2023

Evolus to Participate in September Conferences

August 23, 2023

Evolus Announces Inducement Grants for New Chief Marketing Officer

August 21, 2023

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

August 08, 2023

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers

August 02, 2023

Evolus Reports Second Quarter 2023 Results and Provides Business Update

July 27, 2023

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

July 26, 2023

Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

July 19, 2023

Evolus to Report Second Quarter 2023 Results and Provide Business Update

June 29, 2023

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

June 22, 2023

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

June 08, 2023

Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program

May 09, 2023

Evolus Reports First Quarter 2023 Results and Provides Business Update

May 09, 2023

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

May 05, 2023

Evolus to Report First Quarter 2023 Results and Provide Business Update

March 08, 2023

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

February 28, 2023

Evolus to Participate in the Barclays Global Healthcare Conference

February 27, 2023

Evolus Initiates Nuceiva® Launch in Germany and Austria

February 22, 2023

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

February 10, 2023

Evolus Not Affected by Recent Korean Court Ruling

January 31, 2023

Evolus to Participate in the SVB Securities Global Biopharma Conference

January 28, 2023

"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance

January 23, 2023

Evolus Receives Regulatory Approval for Nuceiva® in Australia

January 23, 2023

Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress

January 18, 2023

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration

December 08, 2022

Evolus Extends Term of Credit Facility with Pharmakon Advisors

December 07, 2022

Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc.

November 08, 2022

Evolus Reports Third Quarter 2022 Results and Provides Business Update

November 02, 2022

Evolus to Participate in November Conferences

October 25, 2022

Evolus to Report Third Quarter 2022 Results and Provide Business Update

October 04, 2022

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

September 21, 2022

Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

September 06, 2022

Evolus Announces Inducement Grants for New Chief Financial Officer

August 30, 2022

Evolus Appoints Sandra Beaver as Chief Financial Officer

August 29, 2022

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 24, 2022

Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

August 02, 2022

Evolus Reports Second Quarter 2022 Results and Provides Business Update

July 19, 2022

Evolus to Report Second Quarter 2022 Results and Provide Business Update

July 19, 2022

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

April 26, 2022

Evolus to Report First Quarter 2022 Results and Provide Business Update

March 31, 2022

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®